Niagen Bioscience, Inc. (NAGE)Healthcare | Biotechnology | Los Angeles, United States | NasdaqCM
3.47 USD
+0.08
(2.360%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.42 -0.05 (-0.046%) ⇩ (July 13, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:38 a.m. EDT
The investment thesis here rests entirely on the company's exceptional long-term business quality, which has been vindicated by a massive +189% cumulative gain over the last nine years and a robust 27% return on equity. However, the stock is currently in a painful correction phase, trading nearly 40% below its 200-day average and struggling to recover from a recent earnings miss. While the fundamentals—driven by their NAD+ science and drug development pipeline—are objectively strong, the short-term momentum is weak, and the statistical forecasting models offer no reliable directional signal due to extreme noise. The options market tells a different story, with traders aggressively buying calls at higher strikes, suggesting a belief that the current price is a temporary dislocation rather than a permanent failure. For a patient investor, the gap between the superior long-term fundamentals and the depressed short-term price presents a compelling entry point, provided one can ignore the immediate volatility and the lack of a dividend yield. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.266726 |
| MSTL | 0.269070 |
| AutoTheta | 0.277201 |
| AutoARIMA | 0.291877 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 3.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.003 |
| Excess Kurtosis | 0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.129 |
| Revenue per Share | 1.636 |
| Market Cap | 276,365,824 |
| Trailing P/E | 16.52 |
| Forward P/E | 10.84 |
| Beta | 2.08 |
| Profit Margins | 14.29% |
| Previous Name | ChromaDex Corporation |
| Website | https://www.niagenbioscience.com |
As of July 11, 2026, 6:38 a.m. EDT: Speculators are overwhelmingly bullish, positioning heavy call volume and open interest at strikes significantly above the current price ($5.00 and $7.50 for August and November expirations). This aggressive upside skew contrasts sharply with the near-absence of put activity, indicating a strong speculative bet on a rally despite the stock's recent underperformance relative to its moving averages.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6989343 |
| Address1 | 10,900 Wilshire Blvd |
| Address2 | Suite 600 |
| All Time High | 23.66 |
| All Time Low | 0.33 |
| Ask | 4.35 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 810,170 |
| Average Daily Volume3 Month | 850,926 |
| Average Volume | 850,926 |
| Average Volume10Days | 810,170 |
| Beta | 2.083 |
| Bid | 2.51 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.034 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.47 |
| Current Ratio | 4.606 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.54 |
| Day Low | 3.355 |
| Debt To Equity | 3.129 |
| Display Name | Niagen Bioscience |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Growth | 0.167 |
| Earnings Quarterly Growth | 0.248 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | 11,981,000 |
| Ebitda Margins | 0.09187 |
| Enterprise To Ebitda | 17.789 |
| Enterprise To Revenue | 1.634 |
| Enterprise Value | 213,124,304 |
| Eps Forward | 0.32 |
| Eps Trailing Twelve Months | 0.21 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7286 |
| Fifty Day Average Change | -0.2586 |
| Fifty Day Average Change Percent | -0.069355786 |
| Fifty Two Week Change Percent | -69.89343 |
| Fifty Two Week High | 11.58 |
| Fifty Two Week High Change | -8.11 |
| Fifty Two Week High Change Percent | -0.7003454 |
| Fifty Two Week Low | 3.18 |
| Fifty Two Week Low Change | 0.28999996 |
| Fifty Two Week Low Change Percent | 0.09119496 |
| Fifty Two Week Range | 3.18 - 11.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,214,400,600,000 |
| Float Shares | 59,592,724 |
| Forward Eps | 0.32 |
| Forward P E | 10.84375 |
| Free Cashflow | -1,196,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 117 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.64282 |
| Gross Profits | 83,834,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29264 |
| Held Percent Institutions | 0.47162 |
| Implied Shares Outstanding | 79,644,327 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,460,505,600 |
| Last Split Factor | 1:3 |
| Long Business Summary | Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California. |
| Long Name | Niagen Bioscience, Inc. |
| Market | us_market |
| Market Cap | 276,365,824 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_5034211 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | 18,637,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 269,994,268 |
| Number Of Analyst Opinions | 6 |
| Open | 3.49 |
| Operating Cashflow | 4,427,000 |
| Operating Margins | 0.05007 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 310 388 6706 |
| Post Market Change | -0.045900106 |
| Post Market Change Percent | -1.3227696 |
| Post Market Price | 3.4241 |
| Post Market Time | 1,783,986,498 |
| Prev Name | ChromaDex Corporation |
| Previous Close | 3.39 |
| Price Hint | 4 |
| Price To Book | 3.3558993 |
| Price To Sales Trailing12 Months | 2.1191099 |
| Profit Margins | 0.1429 |
| Quick Ratio | 3.482 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0799999 |
| Regular Market Change Percent | 2.35988 |
| Regular Market Day High | 3.54 |
| Regular Market Day Low | 3.355 |
| Regular Market Day Range | 3.355 - 3.54 |
| Regular Market Open | 3.49 |
| Regular Market Previous Close | 3.39 |
| Regular Market Price | 3.47 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,095,860 |
| Return On Assets | 0.07091 |
| Return On Equity | 0.27074 |
| Revenue Growth | 0.033 |
| Revenue Per Share | 1.636 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 79,644,327 |
| Shares Percent Shares Out | 0.0552 |
| Shares Short | 4,394,606 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,715,950 |
| Short Name | Niagen Bioscience, Inc. |
| Short Percent Of Float | 0.0847 |
| Short Ratio | 6.07 |
| Source Interval | 15 |
| State | CA |
| Symbol | NAGE |
| Target High Price | 18.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 11.5 |
| Total Cash | 66,397,000 |
| Total Cash Per Share | 0.832 |
| Total Debt | 2,576,000 |
| Total Revenue | 130,416,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.21 |
| Trailing P E | 16.52381 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.54145 |
| Two Hundred Day Average Change | -2.07145 |
| Two Hundred Day Average Change Percent | -0.3738101 |
| Type Disp | Equity |
| Volume | 1,095,860 |
| Website | https://www.niagenbioscience.com |
| Zip | 90,024 |